PeptideWiki

Cagrilintide: what the amylin analog's trials show and where FDA review stands

Published by the PeptideWiki editorial team.

Cagrilintide

Cagrilintide is an investigational long-acting amylin analog. Phase 2 data showed 6.0–10.8% weight loss at 26 weeks; with semaglutide, REDEFINE 1 reported 20.4% at 68 weeks.

Cagrilintide is an investigational, long-acting analog of the hormone amylin, developed by Novo Nordisk. It has no FDA approval, alone or in combination. Most of its human data come from trials of CagriSema, a fixed combination of cagrilintide with semaglutide. This explainer covers what cagrilintide is, what the phase 2 and phase 3 trials reported, and where its development stands in November 2026.

Research material: FAL-CAG at Fifth Ave Labs · LP-Cagr at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

What is cagrilintide?

Amylin is a 37-residue peptide hormone released with insulin from pancreatic beta cells. It is linked to satiety, slower gastric emptying and lower post-meal glucagon. Native human amylin aggregates readily and is short-lived, which limits its use as a drug or research molecule.

Cagrilintide addresses both problems. It carries amino acid substitutions that reduce aggregation, plus a fatty acid side chain that binds albumin and extends its half-life. Several long-acting peptides use the same strategy; see lipidation and half-life extension and peptide aggregation.

It acts on amylin receptors, which are complexes of the calcitonin receptor with RAMP proteins, and on the calcitonin receptor itself. It does not act on the GLP-1 receptor. The only US-approved amylin analog is pramlintide, a short-acting drug approved for use alongside mealtime insulin in diabetes. Structural and analytical notes are on the cagrilintide compound page.

The phase 2 cagrilintide trial

The main dataset for cagrilintide on its own is a 26-week, dose-finding phase 2 trial by Lau and colleagues. It was published in The Lancet in November 2021. It enrolled 706 adults without diabetes at 57 sites in ten countries. Participants had obesity, or overweight with hypertension or dyslipidaemia.

Participants were randomized to one of five once-weekly cagrilintide arms, once-daily liraglutide as an active comparator, or placebo. Mean body-weight reductions ranged from 6.0% to 10.8% across the cagrilintide arms, versus 3.0% with placebo. The highest cagrilintide arm lost more weight than the liraglutide arm (11.5 kg versus 9.6 kg).

Gastrointestinal events were the most frequent adverse events. They occurred in 41% to 63% of participants across cagrilintide groups versus 32% with placebo, mostly nausea. The study was built to select doses for later trials, not to confirm efficacy. Twenty-six weeks is also short for a body-weight endpoint.

CagriSema: cagrilintide with semaglutide in phase 3

Development then shifted to the combination. REDEFINE 1, published in the New England Journal of Medicine in June 2025, randomized 3,417 adults without type 2 diabetes in a 21:3:3:7 ratio. The arms were CagriSema, semaglutide alone, cagrilintide alone and placebo, each with lifestyle intervention for 68 weeks.

Using the treatment-policy estimand, mean weight change was −20.4% with CagriSema versus −3.0% with placebo. Novo Nordisk reports −22.7% versus −2.3% when estimating the effect as if every participant stayed on treatment. In the CagriSema arm, 91.9% reached at least a 5% reduction, against 31.5% on placebo.

REDEFINE 2 enrolled 1,206 adults with type 2 diabetes and compared CagriSema with placebo. Weight change at 68 weeks was −13.7% versus −3.4%. An HbA1c of 6.5% or lower was reached by 74% of the CagriSema group and 15.9% of the placebo group.

TrialPopulationLengthComparisonMean weight change
Phase 2 (Lancet 2021)706 adults without diabetes26 weeksCagrilintide vs placebo and liraglutide−6.0% to −10.8% vs −3.0% placebo
REDEFINE 1 (NEJM 2025)3,417 adults without type 2 diabetes68 weeksCagriSema vs placebo, plus single-agent arms−20.4% vs −3.0% placebo
REDEFINE 2 (NEJM 2025)1,206 adults with type 2 diabetes68 weeksCagriSema vs placebo−13.7% vs −3.4% placebo

Adverse events reported in the trials

In REDEFINE 1, gastrointestinal adverse events affected 79.6% of the CagriSema group and 39.9% of the placebo group. The most common were nausea (55% vs 12.6%), constipation (30.7% vs 11.6%) and vomiting (26.1% vs 4.1%). Discontinuation because of adverse events was 5.9% versus 3.5%. In REDEFINE 2 it was 8.4% versus 3%.

These figures describe the combination, so they cannot be assigned to cagrilintide alone. The sources reviewed for this post did not give a separate phase 3 safety breakdown for the cagrilintide-only arm. Cardiovascular outcome data are also pending; REDEFINE 3 is an ongoing event-driven cardiovascular trial.

Cagrilintide regulatory status in 2026

Novo Nordisk submitted a New Drug Application for CagriSema to the FDA on December 18, 2025. The application seeks approval for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. At filing, the company stated that CagriSema was not approved in the US or EU and that FDA review was expected in 2026.

The FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, states that cagrilintide cannot be used in compounding under federal law. It adds that cagrilintide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. The same page describes warning letters to companies selling unapproved incretin drugs falsely labeled "for research purposes".

Dated changes are logged on the regulatory tracker. For a related investigational incretin, see the retatrutide trial safety summary.

Limits of the evidence

Nearly all human data on cagrilintide come from sponsor-funded trials. Evidence for cagrilintide by itself rests mainly on one 26-week phase 2 study and the smaller single-agent arm of REDEFINE 1. Headline weight figures also depend on which estimand is reported, so numbers differ between sources for the same trial.

Amylin receptor biology differs between species, so animal findings on amylin analogs translate imperfectly to humans. For the incretin programs these trials are often compared with, see the semaglutide, tirzepatide and retatrutide comparison.

Research material: FAL-CAG at Fifth Ave Labs · LP-Cagr at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Sources

  1. Novo Nordisk: Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management (Dec 18, 2025)
  2. U.S. FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of Oct 1, 2026)
  3. American College of Cardiology: REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or Placebo (Jul 2, 2025)
  4. Medical Dialogues: Once-weekly cagrilintide shows promising results for treatment of obesity, summary of Lau et al., The Lancet (Nov 19, 2021)

Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.

More from the blog